Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study

International Clinical Psychopharmacology
Jean-Pierre OliéRuoyong Yang

Abstract

We compared the efficacy of ziprasidone and amisulpride in the treatment of negative symptoms and overall psychopathology in subjects who had chronic schizophrenia with predominantly negative symptoms. This multicentre, 12-week, double-blind study randomly assigned subjects with predominantly negative-symptom schizophrenia [i.e. Positive and Negative Syndrome Scale (PANSS) Negative Subscale score >or=6 points greater than Positive Subscale score] to ziprasidone (40-80 mg b.i.d.; n=60) or amisulpride (50-100 mg b.i.d.; n=63). The primary efficacy variable was the change from baseline in PANSS Negative Subscale score. Secondary efficacy variables included change in scores for PANSS Total, Global Assessment of Functioning, Brief Psychiatric Rating Scale derived from PANSS Total and Core, Clinical Global Impression (CGI)-Severity and CGI-Improvement. For the change in PANSS Negative Subscale score, a ratio to assess the equivalence of the treatment groups was calculated from the least squares mean changes from baseline, with equivalence claimed if the lower limit of the 95% confidence interval of the ratio exceeded 0.60. Mean daily dose, adjusted for differential numbers of subjects and differential days between visits, was 118.0 m...Continue Reading

References

May 1, 1988·The American Journal of Psychiatry·W T CarpenterA M Wagman
Jan 1, 1995·The British Journal of Psychiatry : the Journal of Mental Science·P BoyerF Aubin
Jan 1, 1997·The British Journal of Psychiatry : the Journal of Mental Science·H LooO Fleurot
May 1, 1997·International Clinical Psychopharmacology·W Rein, S Turjanski
Sep 12, 1998·The American Journal of Psychiatry·B C HoN C Andreasen
Apr 8, 1999·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·D G DanielM Lakshminarayanan
Dec 10, 1999·The Journal of Clinical Psychiatry·D N OsserR L Dufresne
Oct 14, 2000·European Psychiatry : the Journal of the Association of European Psychiatrists·P CarrièreT Lempérière
Jul 31, 2001·Journal of Clinical Psychopharmacology·J M Meyer
Jan 22, 2002·International Clinical Psychopharmacology·G B CassanoUNKNOWN AMIMAJOR Group
Jan 24, 2002·The Journal of International Medical Research·T Burns, R Bale
Feb 2, 2002·The American Journal of Psychiatry·Stefan LeuchtWerner Kissling
May 16, 2002·Drugs·Nishan S GunasekaraGillian M Keating
Jun 29, 2002·The Journal of Clinical Psychiatry·Steven R HirschRory O'Connor
May 21, 2003·The Journal of Clinical Psychiatry·Peter J WeidenRichard L O'Sullivan

❮ Previous
Next ❯

Citations

May 16, 2009·Neuropsychology Review·Alice Medalia, Jimmy Choi
Apr 2, 2009·Psychological Medicine·S LeuchtJ M Davis
Jun 13, 2013·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Robert A LasserJean-Pierre Lindenmayer
Feb 1, 2008·Schizophrenia Bulletin·Stefan LeuchtJohn M Kane
Aug 28, 2012·The Journal of Nervous and Mental Disease·Neil Krishan AggarwalRobert A Rosenheck
Apr 26, 2014·PloS One·Maarten BakMarjan Drukker
Feb 4, 2010·Current Medical Research and Opinion·Philippe Nuss, Cedric Tessier
Apr 2, 2011·European Psychiatry : the Journal of the Association of European Psychiatrists·J-M Montes
Mar 27, 2009·Schizophrenia Research·Bruce ParsonsCynthia Siu
Jul 4, 2008·Progress in Neuro-psychopharmacology & Biological Psychiatry·Hsing-Kang ChenNian-Sheng Tzeng
Feb 5, 2008·Schizophrenia Research·Rajiv TandonUNKNOWN Section of Pharmacopsychiatry, World Psychiatric Association
Jul 14, 2007·CNS Drug Reviews·William M Greenberg, Leslie Citrome
Aug 26, 2006·Schizophrenia Research·Brendan P MurphyPatrick D McGorry
Aug 31, 2014·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Eduardo DunayevichJonathan Rabinowitz
Jul 18, 2015·Schizophrenia Research·Jiao WangRaymond C K Chan
Jul 28, 2012·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Alkomiet HasanUNKNOWN World Federation of Societies of Biological Psychiatry (WFSBP) Task Force on Treatment Guidelines for Schizophrenia
Jun 1, 2016·Schizophrenia Research·Armida MucciSilvana Galderisi
Feb 18, 2017·Current Opinion in Psychiatry·Paola Bucci, Silvana Galderisi
Jan 1, 2011·Journal of Central Nervous System Disease·Chiara MatteiStephen M Stahl
Jan 26, 2018·European Archives of Psychiatry and Clinical Neuroscience·Marc KrauseStefan Leucht
Apr 14, 2010·The Journal of ECT·Vasilios G MasdrakisPanagiotis Oulis
Jan 22, 2010·The Cochrane Database of Systematic Reviews·Katja KomossaStefan Leucht
Dec 5, 2006·European Psychiatry : the Journal of the Association of European Psychiatrists·Duerten KudlaDieter Naber
Oct 13, 2009·The Cochrane Database of Systematic Reviews·Katja KomossaStefan Leucht
Mar 27, 2018·Early Intervention in Psychiatry·Lama SouaibyMarie-Odile Krebs
Feb 19, 2021·European Psychiatry : the Journal of the Association of European Psychiatrists·S GalderisiW Gaebel

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.